Pelthos Therapeutics is a freshly recapitalized commercial dermatology company whose entire public-market identity rests on whether an at-home molluscum gel can carry a royalty-laden capital stack. The July combination of Ligand Pharmaceuticals' Zelsuvmi asset into the old Channel Therapeutics shell put the first caregiver-applied prescription for that pediatric poxvirus onto the NYSE American tape in the same month launch began. The second-quarter print is the fourth commercial period and the first clean read on whether prescription growth is pull-through rather than wholesale fill.
Demand is the constructive case. Units dispensed and unique prescribers both rose at a mid-forties sequential pace, and wholesale days on hand declined, which is the opposite of a stuffing quarter. Cash finished mid-year at $24 million. Related-party convertible notes carried near $43 million sit beside a Horizon venture loan of about $27 million. Ligand still collects a low-double-digit royalty on worldwide net sales, and a sales-based milestone inflated selling expense in the period. The common equity is residual after those layers have been paid.
Adjusted operating loss narrowed even as selling expense absorbed a one-time milestone. Coverage at a large pharmacy benefit manager and a pediatrician push are the adoption levers management is leaning on. Shares closed the publication session near $23, implying a common-equity capitalization near $87 million against that stacked claim structure. The question for the next several quarters is whether Zelsuvmi can keep compounding through summer seasonality and a planned rise in gross-to-net deductions, or whether the restated convertible accounting, the thin cash buffer, and two planned relaunches force another financing before the product covers its own royalty stack.